Breaking News Instant updates and real-time market news.

MDXG

MiMedx

$13.51

0.31 (2.35%)

07:32
10/17/17
10/17
07:32
10/17/17
07:32

MiMedx notified by FDA to proceed with Phase 2B IND trial for osteoarthritis

MiMedx has been notified by the FDA that its Investigational New Drug Phase 2B clinical study for osteoarthritis of the knee may proceed. The clinical study consists of a Phase 2B, prospective, double-blinded, randomized controlled trial of MiMedx's AmnioFix Injectable, compared to saline placebo in the treatment of knee osteoarthritis. The trial will enroll approximately 318 patients and the company expects patient enrollment to commence in the next quarter. The company indicated the IND Phase 2 clinical study objective is to determine the safety and effectiveness of AmnioFix Injectable as compared to the 0.9% Sodium Chloride USP placebo injection control for the treatment of osteoarthritis of the knee. The primary efficacy endpoints of this study will be the change in Visual Analog Scale score and the change in Western Ontario and McMaster Universities osteoarthritis index for patients between baseline and Day 90 between the AmnioFix Injectable group versus the placebo-control group.

  • 27

    Oct

  • 08

    Nov

  • 09

    Nov

  • 10

    Nov

  • 13

    Nov

  • 14

    Nov

MDXG MiMedx
$13.51

0.31 (2.35%)

09/22/17
PIPR
09/22/17
NO CHANGE
Target $18
PIPR
Overweight
MiMedx shares offer 'highly attractive entry point,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes the recent pullback in shares in MiMedx Group brings a "highly attractive entry point." Short reports can have a dramatic impact in the short term, but generally end up immaterial, O'Brien tells investors in a research note after MiMedx hosted a business update call and addressed the recent reports. He believes the company has multiple catalysts to drive "significant" revenue growth in the coming years and drive the multiple higher as it transitions to a biopharma company. O'Brien has an Overweight rating on MiMedx with an $18 price target.
09/06/17
NEED
09/06/17
NO CHANGE
NEED
MiMedx should get revenue boost from VLU indication, says Needham
After MiMedx announced that its venous leg ulcer, or VLU, randomized controlled trial was accepted for publication in The International Wound Journal, Needham analyst Mike Matson thinks the results are favorable versus a competing treatment, Organogenesis Apligraf. He estimates that coverage of the VLU indication could generate $75M-$150M of incremental revenue for MiMedx in 2018. He raised his price target on the shares to $21 from $20 and keeps a Strong Buy rating on the stock.
09/05/17
PIPR
09/05/17
NO CHANGE
PIPR
Overweight
MiMedx yearly guidance likely to be raised with Q3 release, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted the strong momentum MiMedx saw in the first half has continued into Q3. While the company said it sees beating its Q3 revenue guidance but left its full year view unchanged for now, he "fully" expects guidance will be raised with its Q3 report. O'Brien recommends investors become increasingly aggressive on pullbacks in MiMedx and keeps an Overweight rating on the shares.
08/31/17
PIPR
08/31/17
NO CHANGE
PIPR
Overweight
Piper says MiMedx study publication provides 'ammuntion' in insurance fight
Piper Jaffray analyst Matt O'Brien believes MiMedx has one of the best products for treating Venous Leg Ulcers, or VLUs, and he sees the publication of their latest peer-reviewed clinical study as "more ammunition" as the company lobbies insurance providers to pay in these cases. With peer-reviewed data in hand, he sees the company announcing positive coverage decisions in the coming quarters, he tells investors. O'Brien keeps an Overweight rating on MiMedx and recommends investors get "increasingly aggressive" on any pullbacks.

TODAY'S FREE FLY STORIES

RHT

Red Hat

$125.50

-1.1 (-0.87%)

15:01
01/18/18
01/18
15:01
01/18/18
15:01
Conference/Events
Red Hat participates in a conference call with Bernstein »

U.S. SMID-Cap Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

RIG

Transocean

$11.40

-0.2138 (-1.84%)

14:59
01/18/18
01/18
14:59
01/18/18
14:59
Hot Stocks
Transocean shareholders approve acquisition of Songa Offshore SE »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVIR

Aviragen

$0.66

0.01 (1.54%)

14:59
01/18/18
01/18
14:59
01/18/18
14:59
Hot Stocks
SC Fundamental lowers stake in Aviragen to 4.83% from 6.19% »

SC Fundamental continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ED

Consolidated Edison

$78.74

-0.535 (-0.67%)

14:45
01/18/18
01/18
14:45
01/18/18
14:45
Hot Stocks
Consolidated Edison boosts quarterly dividend to 71.5c per share »

Consolidated Edison…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$84.00

-0.425 (-0.50%)

14:43
01/18/18
01/18
14:43
01/18/18
14:43
Periodicals
SoftBank closes $1.2B deal to invest in Uber, TechCrunch says »

SoftBank's $1.2B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FE

FirstEnergy

$29.73

-0.195 (-0.65%)

14:31
01/18/18
01/18
14:31
01/18/18
14:31
Conference/Events
FirstEnergy participates in a webcast with Wolfe Research »

Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

COG

Cabot Oil & Gas

$27.76

-0.225 (-0.80%)

14:30
01/18/18
01/18
14:30
01/18/18
14:30
Options
Notable call buying in Cabot Oil and Gas »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
01/18/18
01/18
14:30
01/18/18
14:30
General news
Canada manufacturing preview »

Canada manufacturing…

14:28
01/18/18
01/18
14:28
01/18/18
14:28
Conference/Events
Wolfe Research airlines/A&D analyst holds an analyst/industry conference call »

Airlines and Aerospace…

IIIN

Insteel

$29.83

0.57 (1.95%)

14:27
01/18/18
01/18
14:27
01/18/18
14:27
Downgrade
Insteel rating change  »

Insteel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

URI

United Rentals

$181.44

1.27 (0.70%)

14:25
01/18/18
01/18
14:25
01/18/18
14:25
Options
United Rentals call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

XLK

Technology Select Sector SPDR

$67.80

0.25 (0.37%)

, XLF

Financial Select Sector

$29.41

0.04 (0.14%)

14:17
01/18/18
01/18
14:17
01/18/18
14:17
Technical Analysis
Technical Take: S&P 500 turns positive, bullish intraday pattern active »

The S&P 500 (SPX) has…

XLK

Technology Select Sector SPDR

$67.80

0.25 (0.37%)

XLF

Financial Select Sector

$29.41

0.04 (0.14%)

XLE

Energy Select Sector SPDR

$76.83

-0.28 (-0.36%)

XLV

Health Care Select Sector SPDR

$87.91

-0.18 (-0.20%)

SPY

SPDR S&P 500 ETF Trust

$279.59

-0.02 (-0.01%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
01/18/18
01/18
14:17
01/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/18/18
01/18
14:16
01/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADT

ADT Inc.

, APO

Apollo Global

$35.12

-0.3 (-0.85%)

14:14
01/18/18
01/18
14:14
01/18/18
14:14
Syndicate
ADT Inc. IPO likely to price below $17-$19 range, WSJ reports »

ADT's (ADT) initial…

ADT

ADT Inc.

APO

Apollo Global

$35.12

-0.3 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 19

    Jan

FB

Facebook

$177.60

-0.79 (-0.44%)

, AXP

American Express

$100.17

-0.59 (-0.59%)

14:12
01/18/18
01/18
14:12
01/18/18
14:12
Hot Stocks
Facebook appoints American Expres CEO Chenault to board »

Facebook (FB) announced…

FB

Facebook

$177.60

-0.79 (-0.44%)

AXP

American Express

$100.17

-0.59 (-0.59%)

IBM

IBM

$169.03

0.38 (0.23%)

PG

Procter & Gamble

$90.28

-0.2304 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 16

    Feb

  • 28

    Feb

TTWO

Take-Two

$116.09

2.13 (1.87%)

14:05
01/18/18
01/18
14:05
01/18/18
14:05
Options
TakeTwo Interactive Software call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGNX

MacroGenics

$19.85

0.07 (0.35%)

14:01
01/18/18
01/18
14:01
01/18/18
14:01
Hot Stocks
MacroGenics 'encouraged' by sudy of margetuximab plus pembrolizumab »

MacroGenics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

13:55
01/18/18
01/18
13:55
01/18/18
13:55
Conference/Events
House Homeland Security Committee to hold a hearing »

The Transportation and…

QEP

QEP Resources

$10.93

-0.04 (-0.36%)

13:55
01/18/18
01/18
13:55
01/18/18
13:55
Conference/Events
House Committee on Natural Resources to hold an oversight hearing »

The Subcommittee on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

JAGX

Jaguar Health

$0.14

0.002 (1.43%)

13:53
01/18/18
01/18
13:53
01/18/18
13:53
Conference/Events
Jaguar Health to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTCT

PTC Therapeutics

$21.95

0.46 (2.14%)

13:51
01/18/18
01/18
13:51
01/18/18
13:51
Periodicals
PTC raised price of muscular-dystrophy drug by 9%, WSJ reports »

PTC Therapeutics raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTX

Manitex

$9.63

0.11 (1.16%)

13:48
01/18/18
01/18
13:48
01/18/18
13:48
Hot Stocks
Manitex announces $6.3M order for cranes »

Manitex International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$7.73

-0.43 (-5.27%)

13:45
01/18/18
01/18
13:45
01/18/18
13:45
Options
Helios and Matheson call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

13:41
01/18/18
01/18
13:41
01/18/18
13:41
Periodicals
Amazon sends team to Israel to determine market conditions, Globes reports »

Amazon sent a team to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.